Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Synermore

Synermore
2013 FOUNDED
PRIVATE STATUS
81-90 EMPLOYEES
Early Stage VC LATEST DEAL TYPE
$27.6M LATEST DEAL AMOUNT
2 INVESTORS
Description

Developer of biotechnology services intended to focus on research and development of innovative and biosimilar monoclonal antibodies. The company's services primary researches to bring products from research stage through IND-enabling nonclinical and CMC activities to clinical stage of development, enabling clients to launch their products with certification.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Primary Office
  • 6F-6, Number 5
  • Alley 22, Lane 513, Ruiquang Road
  • Taipei City, Neihu District 114-92
  • Taiwan

+886 02 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Synermore’s full profile, request a free trial.

Synermore Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 01-Dec-2016 $27.6M 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 11-Feb-2015 00.000 000.00 Completed Generating Revenue
1. Early Stage VC $20.6M $20.6M Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

Synermore Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
CDIB Capital Group Venture Capital Minority 000 0000 000000 0
Morningside Group PE/Buyout Minority 000 0000 000000 0

Synermore Executive Team (3)

Name Title Board
Seat
Contact
Info
Eric Tsao Chief Executive Officer
Perky Huang Ph.D Chief Financial Officer
Feng Mao Ph.D Vice President, Process Development